TAILIEUCHUNG - Chapter 104. Acute and Chronic Myeloid Leukemia (Part 13)

Chronic Myelogenous Leukemia: Treatment The therapy of CML is changing rapidly because we have a proven curative treatment (allogeneic transplantation) that has significant toxicity and a new targeted treatment (imatinib) with excellent outcome based on 5-year follow-up data. Therefore, physician experience and patient preference must be factored into the treatment selection process. Discussion of both treatment options with a patient is indicated. The decision should focus on the outcomes, risks, and toxicities of the various approaches. At present, the goal of therapy in CML is to achieve prolonged, durable, nonneoplastic, nonclonal hematopoiesis, which entails the eradication of any residual cells containing the. | Chapter 104. Acute and Chronic Myeloid Leukemia Part 13 Chronic Myelogenous Leukemia Treatment The therapy of CML is changing rapidly because we have a proven curative treatment allogeneic transplantation that has significant toxicity and a new targeted treatment imatinib with excellent outcome based on 5-year follow-up data. Therefore physician experience and patient preference must be factored into the treatment selection process. Discussion of both treatment options with a patient is indicated. The decision should focus on the outcomes risks and toxicities of the various approaches. At present the goal of therapy in CML is to achieve prolonged durable nonneoplastic nonclonal hematopoiesis which entails the eradication of any residual cells containing the BCR ABL transcript. Hence the goal is complete molecular remission and cure. A proposed imatinib treatment algorithm for the newly diagnosed CML patient is presented in Table 104-4. Table 104-4 Imatinib Treatment Milestones for Newly Diagnosed CML Patients Proposed Course of Action Transplantation from an HLA-compatible related or unrelated donor dasatinib new drugs Continue same0 or increase dosec Time months Milestones 3 No complete hematologic remission Complete hematologic remission 6 No cytogenetic remission Any cytogenetic remission6 12 Minor6 or no cytogenetic remission C omplctc A or partial6 g cytogenetic remission 18 Partial minor or no cytogenetic remission Complete cytogenetic remission Anytime Loss of previously achieved hematologic cytogenetic or molecular remission Nutritional Comprehensive Cancer Network Chronic myelogenous leukemia. Denotes that at the indicated milestones patients should stay on the same dose. cDenotes that at the indicated milestones for patients on 400 mg d one can either continue the same or increase the dose to a maximum of 600-800 mg .

• Y học thường thức
• Acute and Chronic Myeloid Leukemia
• bệnh học và điều trị
• bài giảng bệnh học
• tài liệu học ngành y
• Harrisons Internal Medicine
• Chronic myeloid leukemia
• Acute myeloid leukemia
• Imatinib mesylate
• Leukemia markers
• Anti leukemia drugs in myeloid leukemia
• BMC Cancer
• Acute lymphoblastic leukemia
• Chronic lymphocytic leukemia
• Case rep
• Chemotherapeutic agents
• Phase I
• Myelodysplastic syndrome
• Chronic myelomonocytic leukemia
• Acute lympho leukemia
• Hyperleukocytic symptoms
• Clinical symptoms of leukostatsis
• Pathology competencies
• Organ system pathology
• Myeloid neoplasia
• Myelodysplastic syndromes
• Myeloproliferative neoplasms
• Tobacco smoking
• Including chronic myeloid leukemia
• Tyrosine kinase inhibitor
• Hematopoietic stem cell transplantation
• Kinase inhibitors
• báo cáo khoa học
• báo cáo y học
• công trình nghiên cứu về y học
• tài liệu về y học
• cách trình bày báo cáo